The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study

Satu Mustjoki,Johan Richter,Gisela Barbany,Ingunn Dybedal,Thoas Fioretos,Tobias Gedde-Dahl,Bjørn Tore Gjertsen,Randi Hovland,Sari E. Jalkanen,Dag Josefsen,Perttu Koskenvesa,Carin Lassen,Kirsi Latvala,Waleed Majeed,Claes Malm,Berit Markevärn,Ali Moshfegh,Lotta Ohm,Tor Olofsson,Ulla Strömberg,Katrin Rapakko,Kari Remes,Jesper Stentoft,Leif Stenke,Merja Suominen,Sara Thunberg,Ole Weiss Bjerrum,Bengt Simonsson,Kimmo Porkka,Henrik Hjorth Hansen

The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study

2010

The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study

Keywords:

Bone marrow
Immunology
Myeloid leukemia
Stem cell
Low hemoglobin
CD38
CD34
Toxicity
Medicine
Diabetes mellitus
Dasatinib
Hematology
Neutropenia
Internal medicine
imatinib mesylate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations